Quantum.Tech World 2026 is the leading global event uniting the full advanced computing ecosystem across quantum, AI, and high-performance computing. Taking place in Boston on June 25–26, the event brings together 1,000+ senior decision-makers, 150+ speakers, and all 17 U.S. Department of Energy National Laboratories under one roof.
Focused on real-world deployment, Quantum.Tech World goes beyond theory to showcase how organisations are integrating quantum technologies alongside AI and HPC to drive competitive advantage, security, and innovation. Attendees span enterprise, government, academia, and start-ups, creating a unique environment for collaboration, partnership building, and knowledge exchange.
The agenda covers key industries including finance, pharma, aerospace and defence, energy, and advanced research, with practical insights into use cases, infrastructure, and implementation strategies. Co-located with Nexus X, the event highlights the convergence of emerging technologies shaping the future of computing.
From senior enterprise leaders to pioneering researchers, Quantum.Tech World is where the conversations, connections, and decisions defining the next decade of technology happen.
Click here for more information
A:
Quantum.Tech World 2026 brings together the full tech stack — quantum, AI, and HPC — that is collectively reshaping pharmaceutical R&D. The event is where next-gen tech converges to create the tech stack of the future. For pharma, that convergence is not theoretical — it's already producing results in drug discovery pipelines, and we've built content specifically around that reality, with speakers from companies like Moderna, AbbVie, Amgen, and Chugai Pharmaceutical bringing real-world insight to the floor.
Quantum.Tech World 2026 brings together the full tech stack — quantum, AI, and HPC — that is collectively reshaping pharmaceutical R&D. The event is where next-gen tech converges to create the tech stack of the future. For pharma, that convergence is not theoretical — it's already producing results in drug discovery pipelines, and we've built content specifically around that reality, with speakers from companies like Moderna, AbbVie, Amgen, and Chugai Pharmaceutical bringing real-world insight to the floor.
A:
The honest answer is that the industry told us to. When we look at where enterprise quantum teams are being built, the people leading those efforts are also responsible for AI infrastructure and HPC. These aren't separate conversations anymore. HPC, AI and Quantum have a symbiotic relationship and as tech stacks they are converging. For pharma specifically, the convergence of HPC, AI, and quantum computing is transforming drug discovery by enabling rapid screening of vast chemical spaces with AI, refining candidates through HPC simulations, and applying quantum methods to tackle the hardest molecular interactions. We built Nexus X precisely to reflect that reality.
The honest answer is that the industry told us to. When we look at where enterprise quantum teams are being built, the people leading those efforts are also responsible for AI infrastructure and HPC. These aren't separate conversations anymore. HPC, AI and Quantum have a symbiotic relationship and as tech stacks they are converging. For pharma specifically, the convergence of HPC, AI, and quantum computing is transforming drug discovery by enabling rapid screening of vast chemical spaces with AI, refining candidates through HPC simulations, and applying quantum methods to tackle the hardest molecular interactions. We built Nexus X precisely to reflect that reality.
A:
This year we have a more deliberate pharma and healthcare presence than ever before. We have senior figures from GSK, Moderna, AbbVie, Amgen, Roche, Cleveland Clinic, and Chugai Pharmaceutical all on the speaker roster. The fusion of HPC, AI, and quantum computing is enabling precision healthcare through faster diagnostics, personalized treatment planning, and accelerated genomic analysis — and we're covering all of that through dedicated sessions, case studies, and the Nexus X zone. Pharma attendees won't need to extrapolate from other sectors; they'll be hearing directly from their peers.
This year we have a more deliberate pharma and healthcare presence than ever before. We have senior figures from GSK, Moderna, AbbVie, Amgen, Roche, Cleveland Clinic, and Chugai Pharmaceutical all on the speaker roster. The fusion of HPC, AI, and quantum computing is enabling precision healthcare through faster diagnostics, personalized treatment planning, and accelerated genomic analysis — and we're covering all of that through dedicated sessions, case studies, and the Nexus X zone. Pharma attendees won't need to extrapolate from other sectors; they'll be hearing directly from their peers.
A:
We're in a genuinely exciting transition period. Quantum advantage for small-molecule simulation is already within sight, particularly when quantum is used in hybrid workflows alongside HPC. The honest answer is that for full molecular simulation at pharmaceutical scale, we're still a few years away from fault-tolerant, fully practical advantage — but the value is being captured right now through hybrid approaches. That's exactly why we focus on the integrated tech stack rather than waiting for a "pure quantum" moment that may still be years away.
We're in a genuinely exciting transition period. Quantum advantage for small-molecule simulation is already within sight, particularly when quantum is used in hybrid workflows alongside HPC. The honest answer is that for full molecular simulation at pharmaceutical scale, we're still a few years away from fault-tolerant, fully practical advantage — but the value is being captured right now through hybrid approaches. That's exactly why we focus on the integrated tech stack rather than waiting for a "pure quantum" moment that may still be years away.
A:
Nexus X is the natural home for pharma attendees — it's your gateway to explore this convergence, where the future of computing is being built today. Beyond that, the Quantum.Innovation zone will feature the most applied industry case studies. We also have over 20 hours of new industry case studies and 10+ hours of training, upskilling and certification, much of which will be applicable to life sciences professionals. The Breakfast Briefing Workshops are also an opportunity to go deeper on specific use cases in a smaller, more focused setting.
Nexus X is the natural home for pharma attendees — it's your gateway to explore this convergence, where the future of computing is being built today. Beyond that, the Quantum.Innovation zone will feature the most applied industry case studies. We also have over 20 hours of new industry case studies and 10+ hours of training, upskilling and certification, much of which will be applicable to life sciences professionals. The Breakfast Briefing Workshops are also an opportunity to go deeper on specific use cases in a smaller, more focused setting.
A:
Attendees will hear directly from practitioners on use cases including generative chemistry and AI-quantum hybrid approaches to molecular design. AI and Quantum together enable breakthroughs like quantum-enhanced machine learning and generative chemistry. We have speakers from Moderna and AbbVie presenting on quantum algorithms and applications in drug discovery, as well as Amgen sharing work from their Center for Research Acceleration by Digital Innovation. Chugai Pharmaceutical will also be on stage discussing their quantum data science work. These aren't pilot projects — these are programmes with real momentum.
Attendees will hear directly from practitioners on use cases including generative chemistry and AI-quantum hybrid approaches to molecular design. AI and Quantum together enable breakthroughs like quantum-enhanced machine learning and generative chemistry. We have speakers from Moderna and AbbVie presenting on quantum algorithms and applications in drug discovery, as well as Amgen sharing work from their Center for Research Acceleration by Digital Innovation. Chugai Pharmaceutical will also be on stage discussing their quantum data science work. These aren't pilot projects — these are programmes with real momentum.
A:
The event features 150+ expert speakers across government, national labs, enterprise, and academia. From pharma and healthcare specifically, attendees will hear from Alexey Galda, Associate Scientific Director for Quantum Algorithms and Applications at Moderna; Brian Martin, Chief AI Product Owner at AbbVie; Ahmad Sheikh, AbbVie's Global Head of Molecular Profiling and Drug Delivery; Marti S. Head from Amgen; Lara Jehi, Chief Research Information Officer at Cleveland Clinic; Christine Bakan, Group VP at Roche; and Michael Elmore, SVP and Global CISO at GSK. That's a genuinely impressive concentration of pharma quantum expertise in one place.
The event features 150+ expert speakers across government, national labs, enterprise, and academia. From pharma and healthcare specifically, attendees will hear from Alexey Galda, Associate Scientific Director for Quantum Algorithms and Applications at Moderna; Brian Martin, Chief AI Product Owner at AbbVie; Ahmad Sheikh, AbbVie's Global Head of Molecular Profiling and Drug Delivery; Marti S. Head from Amgen; Lara Jehi, Chief Research Information Officer at Cleveland Clinic; Christine Bakan, Group VP at Roche; and Michael Elmore, SVP and Global CISO at GSK. That's a genuinely impressive concentration of pharma quantum expertise in one place.
A:
By integrating quantum, HPC, and AI, organisations can dramatically accelerate innovation, solve previously intractable problems, and make smarter, data-driven decisions. For pharma, Nexus X is where those three capabilities meet in practice. It's not about showcasing technology in isolation — it's about demonstrating what hybrid workflows actually look like when deployed in a research context. Attendees will see how quantum + HPC hybrid platforms from leaders like IBM are fusing quantum capabilities with classical HPC to tackle scientific computing challenges at scale.
By integrating quantum, HPC, and AI, organisations can dramatically accelerate innovation, solve previously intractable problems, and make smarter, data-driven decisions. For pharma, Nexus X is where those three capabilities meet in practice. It's not about showcasing technology in isolation — it's about demonstrating what hybrid workflows actually look like when deployed in a research context. Attendees will see how quantum + HPC hybrid platforms from leaders like IBM are fusing quantum capabilities with classical HPC to tackle scientific computing challenges at scale.
A:
This is perhaps our most important function for the pharma sector right now. Many organisations have completed proof-of-concept work and are asking the harder question: how do we scale? We address this through the case study programme — 20+ hours of new industry case studies — where companies share what worked, what didn't, and what the path to production actually looks like.
This is perhaps our most important function for the pharma sector right now. Many organisations have completed proof-of-concept work and are asking the harder question: how do we scale? We address this through the case study programme — 20+ hours of new industry case studies — where companies share what worked, what didn't, and what the path to production actually looks like.
A:
The Start-Up Zone and Pitchfest are specifically designed to give emerging companies a high-visibility platform in front of decision-makers. Attendees span 1,000+ innovators, leaders, and decision-makers from 40+ countries, including pharma executives actively looking for technology partners. For a biotech startup working on quantum-enabled drug design or diagnostics, that's an extraordinary opportunity for both commercial conversations and investment exposure.
The Start-Up Zone and Pitchfest are specifically designed to give emerging companies a high-visibility platform in front of decision-makers. Attendees span 1,000+ innovators, leaders, and decision-makers from 40+ countries, including pharma executives actively looking for technology partners. For a biotech startup working on quantum-enabled drug design or diagnostics, that's an extraordinary opportunity for both commercial conversations and investment exposure.
A:
The Quantum.Tech Hosted Buyers Club is a premium networking platform designed to foster meaningful relationships between senior decision-makers and solution providers across the quantum ecosystem. Through tailored, 1:1 meetings, we connect executives and procurement leaders with the partners who can address their most pressing challenges. For pharma procurement leaders, the double opt-in matchmaking ensures that every 15-minute meeting delivers value and relevance to your needs — no cold conversations, no wasted time. It compresses months of vendor evaluation into two days.
The Quantum.Tech Hosted Buyers Club is a premium networking platform designed to foster meaningful relationships between senior decision-makers and solution providers across the quantum ecosystem. Through tailored, 1:1 meetings, we connect executives and procurement leaders with the partners who can address their most pressing challenges. For pharma procurement leaders, the double opt-in matchmaking ensures that every 15-minute meeting delivers value and relevance to your needs — no cold conversations, no wasted time. It compresses months of vendor evaluation into two days.
A:
Absolutely critical — and an area we've invested in heavily this year. Quantum literacy across pharma R&D teams is a genuine bottleneck to adoption. You can have the most powerful quantum chemistry platform available, but if your scientists and IT leaders can't evaluate it intelligently, you won't deploy it effectively. We see education as part of the commercialisation pathway, not an add-on.
Absolutely critical — and an area we've invested in heavily this year. Quantum literacy across pharma R&D teams is a genuine bottleneck to adoption. You can have the most powerful quantum chemistry platform available, but if your scientists and IT leaders can't evaluate it intelligently, you won't deploy it effectively. We see education as part of the commercialisation pathway, not an add-on.
A:
The Quantum.Security zone and Quantum.Policy zone both speak directly to these concerns. Post-quantum cryptography is not just a defence or finance issue — pharma companies hold vast amounts of sensitive clinical and genomic data that needs to be protected against future quantum threats. The event features new Quantum Policy Working Groups shaping standards, governance, and real-world deployment across global markets. With speakers like NIST's Lily Chen, the NSA's Adrian Stanger, and healthcare-focused voices from NIH's NCATS, we're covering the full regulatory landscape.
The Quantum.Security zone and Quantum.Policy zone both speak directly to these concerns. Post-quantum cryptography is not just a defence or finance issue — pharma companies hold vast amounts of sensitive clinical and genomic data that needs to be protected against future quantum threats. The event features new Quantum Policy Working Groups shaping standards, governance, and real-world deployment across global markets. With speakers like NIST's Lily Chen, the NSA's Adrian Stanger, and healthcare-focused voices from NIH's NCATS, we're covering the full regulatory landscape.
A:
It's the only way it happens at pace. No single organisation has all the pieces — the quantum hardware expertise sits in companies like IBM, IonQ, and QuEra; the algorithmic research comes from universities and national labs; and the domain knowledge in molecular biology and clinical translation sits inside pharma. The event brings together 50+ industry partners, research development agencies, research labs and associations precisely to enable that multi-stakeholder collaboration. Quantum.Tech World is explicitly designed as a convergence point for all three communities.
It's the only way it happens at pace. No single organisation has all the pieces — the quantum hardware expertise sits in companies like IBM, IonQ, and QuEra; the algorithmic research comes from universities and national labs; and the domain knowledge in molecular biology and clinical translation sits inside pharma. The event brings together 50+ industry partners, research development agencies, research labs and associations precisely to enable that multi-stakeholder collaboration. Quantum.Tech World is explicitly designed as a convergence point for all three communities.
A:
Success is when a pharma R&D leader leaves Boston on June 26th with a clear quantum roadmap, a shortlist of credible technology partners, and the confidence that their team has the skills to execute it.
Success is when a pharma R&D leader leaves Boston on June 26th with a clear quantum roadmap, a shortlist of credible technology partners, and the confidence that their team has the skills to execute it.
A:
Registration for Quantum.Tech World is now open. Join 1,000+ leaders across quantum, AI, HPC, cybersecurity, enterprise, government, and academia in Boston on June 25–26. Complimentary expo passes are still available, but numbers are limited, so secure your place today via the event website: Click Here
Registration for Quantum.Tech World is now open. Join 1,000+ leaders across quantum, AI, HPC, cybersecurity, enterprise, government, and academia in Boston on June 25–26. Complimentary expo passes are still available, but numbers are limited, so secure your place today via the event website: Click Here
